Howard A. Burris, MD. Phase 1 Safety of ICOS Agonist Antibody JTX-2011 Alone and with Nivolumab (nivo) in Advanced Solid Tumors; Predicted vs Observed Pharmacokinetics (PK) in ICONIC. Presented at the ASCO Annual Meeting, June 5, 2017.
Contact Us
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Eric Laub
(857) 259-3853 elaub@jouncetx.com